John Wiley & Sons (WLYB) concentration risks

The company's primary disclosed concentration is a high-share product tilt toward Research: Research revenue accounted for approximately 64% of consolidated revenue in the year ended April 30, 2025. This is a large, structurally rooted exposure — the business is deliberately organized around academic and scientific publishing, so the concentration reflects strategic positioning rather than reliance on any single customer or buyer. Recurring subscription dynamics in the Research segment provide some revenue predictability, but the heavy weighting also means the business is meaningfully exposed to structural pressures facing academic publishing: institutional budget constraints, the evolution of open-access mandates, and longer-term shifts in how research content is disseminated and funded. Because all other revenue lines — such as learning and professional services — each represent a substantially smaller portion of the mix, a sustained deterioration in Research demand or pricing would flow through to consolidated results with limited offset from other segments. No customer, geographic, or supplier concentration is separately disclosed at a comparable scale, which means the product tilt is the dominant concentration risk in the filing. For investors, the key monitoring variable is the trajectory of Research subscription renewals, library consortium pricing, and the pace at which open-access transition models displace traditional subscriptions — all of which bear directly on the health of the segment driving nearly two-thirds of revenue.

For the engine’s reasoning on WLYB’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.